二尖瓣经导管缘对缘修复:有无现场心脏外科中心的同团队对比注册研究
本研究回顾性分析同一介入操作团队在两个中心完成的64例重度(4+)二尖瓣反流患者M-TEER数据,其中无现场心脏外科中心21例,有现场心脏外科中心43例。30天MVARC器械与操作成功率分别为81.0%和72.1%。置信区间较宽,非劣效性未获证实,但支持网络化M-TEER模式的前瞻性评估。
要点
- 同一介入团队在无现场心脏外科中心行M-TEER,30天器械与操作成功率为81.0%。
- 无现场外科中心需通过共享心脏团队及正式紧急转运路径提供外科后备。
- 两组手术中转和院内死亡均为0%,但非劣效性未获证实。
核心结论
- 同一团队比较中,无现场心脏外科中心30天MVARC器械与操作成功率为81.0%,有现场心脏外科中心为72.1%。
- 置信区间较宽,非劣效性未获证实,结果支持对共享介入经验与正式外科后备的网络化M-TEER模式进行前瞻性评估。
研究设计与样本
- 回顾性分析前瞻性收集的注册数据,共64例重度(4+)二尖瓣反流患者,无现场心脏外科中心21例,有现场心脏外科中心43例。
- 两中心共享同一介入操作团队,无现场外科中心通过共享心脏团队和正式紧急转运路径提供外科支持,两组按先后时间段治疗。
主要发现
- MVARC技术成功率分别为100%和97.7%。
- 器械与操作成功率均为81.0%对72.1%,风险差+8.9%,95%CI为−14.9至+27.5,p=0.547。
- 免于主要MVARC严重不良事件的比例为95.2%对95.3%。
- 16例器械成功失败中有12例涉及平均跨二尖瓣压差≥5 mmHg。
- 两组手术中转和院内死亡均为0%。
关键数值与推荐
- 非劣效性分析采用−12.5%和−10%的界值。
- 器械成功失败的主要原因为平均跨二尖瓣压差≥5 mmHg。
临床怎么用
- 网络化M-TEER模式配合共享介入团队和正式紧急转运路径可作为无现场心脏外科中心的可行方案。
- 无现场外科中心开展M-TEER时需建立正式的外科后备和转运机制。
局限性
- 样本量仅64例,置信区间较宽,非劣效性未获证实。
- 两组在先后不同时间段治疗,可能存在时间偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Comparative evidence for M-TEER performed at centers with versus without on-site cardiac surgery is lacking. We compared early outcomes at two centers that shared the same interventional operator team but differed in the availability of on-site cardiac surgery. Methods We retrospectively analyzed prospectively collected registry data from 64 consecutive patients with severe (4+) MR treated at a center without on-site cardiac surgery (no-CCH, n = 21) and a center with on-site cardiac surgery (CCH, n = 43). The same interventional operator team performed every procedure. At the no-CCH center, surgical expertise was provided through a shared Heart Team and a formal emergency transfer pathway. The cohorts were treated in sequential calendar periods. Principal comparative endpoints were MVARC device and procedural success at 30 days. Exploratory non-inferiority analyses used margins of −12.5% and −10%. Results MVARC technical success was 100% versus 97.7%. Device and procedural success were each 81.0% versus 72.1% (risk difference [RD] +8.9%, 95% CI −14.9 to +27.5; p = 0.547). Freedom from major MVARC serious adverse events was 95.2% versus 95.3%. Twelve of 16 device-success failures involved a mean transmitral gradient ≥ 5 mmHg. Surgical conversion and in-hospital death were 0% in both centers. Conclusions In this preliminary same-team comparison, 30-day MVARC device and procedural success rates were 81.0% at the no-CCH center and 72.1% at the CCH center. Confidence intervals were wide and non-inferiority was not established. These findings support prospective evaluation of network-based M-TEER programs with shared interventional expertise and formal surgical backup.
引用
- Catheterization and Cardiovascular Interventions:Mitral Transcatheter Edge‐to‐Edge Repair at Centers With and Without On‐Site Cardiac Surgery: A Comparative Registry With a Shared Interventional Team
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。